Welcome to our dedicated page for Xortx Therapeutics SEC filings (Ticker: XRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XORTX Therapeutics Inc. (XRTX) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. XORTX files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These filings furnish investors with information on financial performance, clinical and regulatory progress, securities offerings, and material corporate developments related to the company’s gout and kidney disease programs.
Recent Form 6-K submissions have included condensed interim consolidated financial statements, management discussion and analysis, and officer certifications, as well as press releases describing registered direct offerings, private placements, Nasdaq minimum bid price notifications, and the binding term sheet to acquire the VB4-P5 renal anti-fibrotic program from Vectus Biosystems Limited. Certain 6-K exhibits, such as legal opinions on the validity of securities, are incorporated by reference into XORTX’s shelf registration statement on Form F-3 (File No. 333-269429).
Through this page, users can review key filing types relevant to XORTX’s sector, including 6-K reports detailing clinical and regulatory updates for the XRx-026 gout program and related XORLO™ formulation, as well as financing structures involving common shares, pre-funded warrants, and agent warrants. The filings also document the company’s responses to Nasdaq listing requirements and its use of at-the-market and registered offerings to fund development of gout, ADPKD, acute kidney injury, and diabetic nephropathy programs.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Real-time updates from EDGAR, along with structured access to XORTX’s 6-K reports and other registered offerings, help investors quickly understand how regulatory events, financings, and clinical disclosures affect the company’s xanthine oxidase–targeted pipeline.
XORTX Therapeutics Inc. filed a Form 6-K to notify shareholders that meeting materials for its upcoming Annual and Special Meeting are now available and have been mailed. The meeting will be held on March 24, 2026 at 10:00 a.m. Calgary time at the company’s Calgary offices.
Shareholders of record as of February 20, 2026 will vote on fixing the board at five directors, electing directors, appointing the auditor and authorizing its remuneration, confirming and approving the stock option plan, and an ordinary resolution to amend the articles to allow a consolidation of the common shares on the basis of up to five pre-consolidation shares for one post-consolidation share. The board unanimously recommends voting for all items, and proxy voting closes on March 20, 2026.
XORTX Therapeutics Inc. is calling an annual and special shareholder meeting on March 24, 2026 to vote on several key corporate items. Shareholders will elect five directors, reappoint Davidson & Company LLP as auditor, and re-approve a rolling stock option plan reserving up to 10% of outstanding common shares for equity incentives.
The company is also asking shareholders to authorize a share consolidation of up to five pre‑consolidation shares for one post‑consolidation share. This flexibility is intended to help XORTX regain compliance with Nasdaq’s US$1.00 minimum bid price requirement before an April 13, 2026 deadline, after which its shares risk delisting if compliance is not restored. As of February 20, 2026, XORTX had 6,962,218 common shares outstanding.
XORTX Therapeutics filed its 2025 audited financial statements and MD&A, showing a net loss of
The auditors and management highlight a material uncertainty that casts significant doubt on XORTX’s ability to continue as a going concern because it must secure additional financing to fund research, clinical trials and operations. In 2025 the company raised equity, issued and exercised pre‑funded warrants, and expanded its warrant structure to fund activities.
XORTX signed a binding term sheet to acquire the VB4‑P5 renal anti‑fibrotic program from Vectus Biosystems for
XORTX Therapeutics Inc. has filed Amendment No. 1 to a Form F-1 to register a primary offering of up to 12,500,000 common shares, 12,500,000 pre-funded warrants, 12,500,000 common warrants and 25,000,000 common shares issuable upon warrant exercises. The securities are offered on a reasonable best efforts basis at an assumed price of $0.40 per share, the recent Nasdaq closing price. Each share or pre-funded warrant is sold together with one common warrant, which will be exercisable for three years at a price no lower than the latest TSXV closing price. XORTX estimates net proceeds of about $4.3 million, intended mainly to fund research and development, working capital and general corporate purposes. The company highlights its late-stage gout program XRx-026, ADPKD program XRx-008, and additional kidney and metabolic disease candidates, while cautioning that investing in the securities involves a high degree of risk and potential dilution.
XORTX Therapeutics Inc. filed a Form 6-K highlighting more time to close its planned acquisition of Vectus Biosystems’ Renal Anti-Fibrotic Therapeutic Program, including the novel compound VB4-P5. An amendment now targets closing on or before March 31, 2026 to complete intellectual property transfer and final documentation.
The company also scheduled its Annual and Special Meeting of Shareholders for March 24, 2026, with shareholders of record on February 20, 2026 eligible to vote. In connection with appointing Krysta Davies Foss to the board, XORTX granted 20,000 stock options at an exercise price of CAD $0.69 for five years.
XORTX Therapeutics Inc. filed a Form 6-K. The filing incorporates Exhibits 99.2 and 99.3 by reference into the company’s Registration Statement on Form F-3 (File No. 333-269429), adding legal opinions regarding the legality of securities being registered from Dentons Canada LLP and Troutman Pepper Locke LLP.
The exhibit index also lists a press release dated October 29, 2025 (Exhibit 99.1). The report is signed by President and Chief Executive Officer Allen Davidoff on October 31, 2025. This is an administrative update linking legal opinions to the existing F-3 shelf.
XORTX Therapeutics Inc. filed a Form 6-K furnishing transaction-related exhibits and incorporating them by reference into its Form F-3 registration statement (File No. 333-269429), as amended and supplemented.
The exhibits include a press release dated October 21, 2025, a Placement Agency Agreement with D. Boral Capital LLC, a form of Securities Purchase Agreement, a form of Lock-Up Agreement, and a form of Pre-Funded Common Share Purchase Warrant. The report was signed by President and CEO Allen Davidoff on October 22, 2025.
XORTX Therapeutics Inc. launched a registered direct offering to an institutional accredited investor, registering 572,470 common shares at $0.63 each, 1,177,530 pre-funded warrants at $0.62999 each with a $0.00001 exercise price, and 1,177,530 common shares underlying those warrants. The pre-funded warrants are immediately exercisable.
The fee table shows an aggregate offering price of $1,102,488, placement agent fees of $77,175, and proceeds before expenses of $1,025,313. The company estimates net proceeds of approximately $0.8 million for working capital and general corporate purposes. A beneficial ownership cap limits exercises above 4.99% (or, at the purchaser’s election at closing, 9.99%).
XRTX trades on the TSXV and Nasdaq. The company has applied to list the Shares and the Pre-Funded Warrant Shares on the TSXV and notified Nasdaq; TSXV approval is required. D. Boral Capital LLC is acting as exclusive placement agent on a best efforts basis. Delivery is expected on or about October 23, 2025, subject to customary conditions and TSXV approvals.